October 16, 2009
It is important to test the 2009 H1N1 influenza vaccine in HIV-infected populations, particularly children, youth and pregnant women, because HIV infection and pregnancy both increase the risk for a poor immune response to the normal 15-microgram dose of seasonal influenza vaccine given to the general population. In addition, children, young people and pregnant women are at higher risk for more severe illness from the 2009 H1N1 influenza virus than other groups, and HIV-infected individuals in these populations may be particularly vulnerable. Because of the increased vulnerability of these populations, these trials are testing whether doses of licensed 2009 H1N1 influenza vaccine that are higher than doses being tested in other groups can safely elicit protective immune responses in HIV-infected children, youth and pregnant women.
One trial will enroll 130 HIV-infected pregnant women ages 18 to 39 years who are in their second or third trimester (14 to 34 weeks) of pregnancy. The other trial will enroll 140 children and youth aged 4 to 24 years who were infected with HIV at birth.
The trial in HIV-infected pregnant women began on October 7, 2009, and the trial in HIV-infected children and youth began on October 14, 2009. Results from both trials will become available during the first quarter of 2010.
The following 35 sites and eight sub-sites across the United States and Puerto Rico are eligible to participate in the trials:
The International Maternal Pediatric Adolescent AIDS Clinical Trials Group is conducting the studies, which are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both part of the National Institutes of Health.
NIAID’s Division of Microbiology and Infectious Diseases is supporting laboratory analyses for the study of the vaccine in HIV-infected pregnant women.
Novartis Vaccines and Diagnostics of Cambridge, Mass., manufactured the 2009 H1N1 influenza vaccine being tested in these clinical trials. This vaccine is licensed by the U.S. Food and Drug Administration.
No. The vaccine is made from an inactivated form of the 2009 H1N1 influenza virus. It is impossible to become infected with the virus by receiving this vaccine.
The vaccine does not contain an adjuvant, a substance that is added to some vaccines to improve the body’s immune response to the vaccine.
The 2009 H1N1 influenza vaccine manufactured by Novartis contains a trace amount of thimerosal, a mercury derivative used in the manufacture of the vaccine and removed by subsequent purification steps. The only known side effects of receiving trace amounts of thimerosal in vaccines have been minor reactions such as redness and swelling at the injection site. More information on the use of thimerosal in vaccines can be found on the Web site of the Centers for Disease Control and Prevention (CDC - Concerns - Mercury and Vaccines (Thimerosal) -Vaccine Safety).
Both trials are Phase II, multi-site, open-label studies.
Participants will receive two 30-microgram doses of the vaccine 21 days apart. The HIV-infected children and youth will be followed for 7 months, while the HIV-infected pregnant women will be followed from the time they enroll in the study until 6 months after giving birth. Their newborns, who will not receive any vaccinations, will be followed for 6 months after birth.
All participants in the trial of pregnant women must be taking antiretroviral therapy (ART).
In the trial with children and youth, participants will be stratified by age into three groups to better monitor age-related variation in their response to the vaccine.
Group 1: 4 to 9 years of age
Group 2: 10 to 17 years of age
Group 3: 18 to 24 years of age
Participating children and youth do not need to be taking ART, but if they are, they must have been on a stable ART regimen for at least 90 days prior to vaccination with no intention to modify the regimen within the next 60 days following study entry. If the children and youth are not on ART, they should not intend to initiate therapy within the next 60 days following study entry.
If a youth becomes pregnant before receiving the second dose of vaccine, that dose will be deferred until at least her 14th week of pregnancy, and she will be followed until up to 28 days after giving birth.
The study team is monitoring the safety of volunteers when they receive their vaccinations and during follow-up visits, and the site investigators and NIH medical officers are monitoring safety on a weekly basis. Also, an independent panel of experts known as a Safety Monitoring Committee is available for ad hoc meetings as needed throughout the trials.
The strength and longevity of the immune response elicited by the vaccine will be gauged in several ways.
The study team will take blood samples from the pregnant women after each dose and 3 and 6 months after delivery to measure the concentration of antibodies the women produce against 2009 H1N1 influenza virus and how strong that antibody response remains over time. After the women give birth, study staff will sample umbilical cord blood to measure the concentration of maternal antibodies against the virus that were transferred to the infants through the placenta. The study team also will collect small blood samples from the infants at 3 and 6 months of age to measure their levels of maternally-derived antibody protection from the virus over time. The infants will not receive the vaccine.
Similarly, in children and young people, the strength and longevity of the immune response will be gauged by testing blood samples taken 21 days after the first dose, 10 days after the second dose, and 6 months after entering the study.
Previous studies have shown that HIV infection increases the risk of inadequate immune responses to standard doses of some vaccines. Research on seasonal influenza vaccine and vaccines for other diseases in HIV-infected and other populations suggest that higher doses of vaccine tend to elicit stronger immune responses. These stronger responses, in turn, increase the concentration of protective antibodies in the bloodstream, which is beneficial to both the vaccinated individual and, if pregnant, to her fetus. This is the rationale for testing whether higher doses of licensed 2009 H1N1 influenza vaccine elicit a protective immune response in HIV-infected individuals and whether that protection is transferred to the fetuses of vaccinated pregnant women.
It is expected that the vaccine will give the infants of vaccinated mothers protection against infection by the 2009 H1N1 influenza virus. This protection likely will result from the transfer of anti-H1N1 influenza antibodies from the vaccinated mother through the placenta to her fetus.
In a study of maternal immunization published in 2008, there was a 63 percent reduction of influenza illness in infants up to 6 months of age whose mothers had received inactivated seasonal influenza vaccine while pregnant. (See K Zaman et al. Effectiveness of maternal influenza immunization in mothers and infants. New England Journal of Medicine DOI:10.1056/NEJMoa0708630 .)
The 2009 H1N1 flu vaccine being tested in this clinical trial is very similar to the annual influenza vaccine recommended by the CDC. The vaccine is produced in the same way as most seasonal flu vaccines: virus is grown in fertilized chicken eggs, then the virus is inactivated and used to make the vaccine. Seasonal inactivated virus influenza vaccines have been used in the United States for decades and have an excellent safety profile.
For information about other NIAID-sponsored clinical trials of 2009 H1N1 flu vaccines, please see the following sets of questions and answers:
Additional information about HIV and H1N1 influenza virus is available from the CDC.
Information for the general public and for healthcare providers about 2009 H1N1 influenza vaccines in pregnant women is available from the CDC.
Also available is a www.flu.gov Web chat on 2009 H1N1 influenza and pregnant women featuring a panel of experts including NIAID Director Anthony S. Fauci, M.D.
For more information about the NIH-sponsored clinical trials of H1N1 influenza vaccine in HIV-infected pregnant women, children and youth, see NIH Launches 2009 H1N1 Influenza Vaccine Trial in HIV-Infected Pregnant Women: Trial in HIV-Infected Children, Youth to Begin Next Week.
Media inquiries can be directed to the NIAID News and Public Information Branch at 301-402-1663, firstname.lastname@example.org.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated October 19, 2009